Overview

• RP1 is a modified HSV-1 virus engineered to eliminate cold-sore genes and boost immune activation against tumor cells.
• In a phase 1–2 trial of 140 patients with immunotherapy-resistant melanoma, one-third achieved at least 30% tumor shrinkage.
• Nearly one in six participants experienced complete regression of injected and uninjected tumors, indicating a systemic response.
• The combination with nivolumab was well tolerated, with mostly mild side effects and a favorable safety profile.
• Following FDA priority review granted in January, a 400-patient global Phase 3 trial has been launched to confirm efficacy.